Allergen specific immunotherapy (IT) represents a cornerstone of @entity2023 treatment and his efficacy has been confirmed, through open and double blind trials and meta-analysis. In the last few years non invasive routs for IT (oromucosal, nasal) were developed gained general acceptation mainly in @entity1 and were validated by WHO. The efficacy of IT could be markers, the pattern of specific antibody response or by the effect on sequential nasal challenges. We have evaluated the effect of IT in @entity2023 by different methods. Nasal IT decreased mean symptoms and pharmacological scores as well as in seasonal as in perennial @entity2490 . The same decrease has been observed after oromucosal IT. The effect of IT in @entity32 has been confirmed by a decrease in the level of soluble adhesion molecule sVCAM-1 which is related to @entity32 but not statistically for sICAM-1. We have also evaluated the immunoblotting pattern or specific IgE after oromucosal IT for house dust mites. For @entity7130 in 4 @entity1 the bands intensity decreased and in 3 @entity1 the bands decreased and in 10 disappeared. IT decreases tryptase and @entity11153 in nasal lavage after sequential nasal challenges. Therefore IT decreases clinical scores, inflammation markers, specific IgE immunoblotting bands and response to allergen challenge. These different results confirm his efficacy and usefulness in @entity2023 .

Immunotherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['allergic inflammation', 'eosinophilic inflammation'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis'] @entity7130 :: ('6956', 'Species') :: ['D. pteronyssinus'] @entity11153 :: ('6037', 'Gene') :: ['ECP'] @entity2490 :: ('MESH:D012220', 'Disease') :: ['rhinitis']
@entity2023 :: (MESH:D006255,Disease) :: ['allergic rhinitis']
